Bo Jansson
Overview
Explore the profile of Bo Jansson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kveton F, Blsakova A, Lorencova L, Jerigova M, Velic D, Blixt O, et al.
Sensors (Basel)
. 2019 Dec;
19(24).
PMID: 31818011
The study describes development of a glycan biosensor for detection of a tumor-associated antibody. The glycan biosensor is built on an electrochemically activated/oxidized graphene screen-printed electrode (GSPE). Oxygen functionalities were...
2.
Wendel U, Persson N, Risinger C, Bengtsson E, Nodin B, Danielsson L, et al.
PLoS One
. 2018 Feb;
13(2):e0191872.
PMID: 29420566
Advanced glycation end products are formed by non-enzymatic reactions between proteins and carbohydrates, causing irreversible lysine and arginine alterations that severely affect protein structure and function. The resulting modifications induce...
3.
Persson N, Stuhr-Hansen N, Risinger C, Mereiter S, Polonia A, Polom K, et al.
Glycobiology
. 2017 Apr;
27(7):635-645.
PMID: 28419225
Here, we introduce a novel scFv antibody, G2-D11, specific for two adjacent Tn-antigens (GalNAc-Ser/Thr) binding equally to three dimeric forms of the epitope, Ser-Thr, Thr-Thr and Thr-Ser. Compared to other...
4.
Kveton F, Blsakova A, Hushegyi A, Damborsky P, Blixt O, Jansson B, et al.
Langmuir
. 2017 Mar;
33(11):2709-2716.
PMID: 28248511
The main aim of the study was to optimize the interfacial presentation of a small antigen-a Tn antigen (N-acetylgalactosamine)-for binding to its analyte anti-Tn antibody. Three different methods for the...
5.
Persson N, Jansson B, Stuhr-Hansen N, Kovacs A, Welinder C, Danielsson L, et al.
PLoS One
. 2016 Dec;
11(12):e0168761.
PMID: 28002485
We have developed a combinatory antibody-antigen microarray for direct screening of multiple single-chain fragment variable (scFv) clones with no need for pre-purification or enrichment before screening. The straightforward workflow allows...
6.
Welinder C, Jirstrom K, Lehn S, Nodin B, Marko-Varga G, Blixt O, et al.
Heliyon
. 2016 Sep;
2(8):e00143.
PMID: 27579449
A high frequency of IgA1-positive tumour cells was found in tissue micro-arrays of oesophagus, colon, testis, lung, breast, bladder and ovarian cancer. IgA1 was observed in the cytoplasm and the...
7.
Welinder C, Pawlowski K, Sugihara Y, Yakovleva M, Jonsson G, Ingvar C, et al.
PLoS One
. 2015 Apr;
10(4):e0123661.
PMID: 25874936
Malignant melanoma has the highest increase of incidence of malignancies in the western world. In early stages, front line therapy is surgical excision of the primary tumor. Metastatic disease has...
8.
Welinder C, Jansson B, Lindell G, Wenner J
Cancer Lett
. 2014 Dec;
358(1):43-6.
PMID: 25528628
Cytokeratin 20 (CK20) is a well-established marker for colon epithelium. Herein, we suggest that CK20 is a biomarker for detecting circulating tumor cells (CTCs) in patients with metastatic colorectal cancer....
9.
Welinder C, Jonsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, et al.
PLoS One
. 2014 Oct;
9(10):e110804.
PMID: 25333933
Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease...
10.
Sugihara Y, Vegvari A, Welinder C, Jonsson G, Ingvar C, Lundgren L, et al.
Proteomics
. 2014 Jul;
14(17-18):1963-70.
PMID: 25044963
Malignant melanoma (MM) patients are being treated with an increasing number of personalized medicine (PM) drugs, several of which are small molecule drugs developed to treat patients with specific disease...